Article ; Online: Epilepsy and brain tumors: Two sides of the same coin.
Journal of the neurological sciences
2023 Volume 446, Page(s) 120584
Abstract: Epilepsy is the most common symptom in patients with brain tumors. The shared genetic, molecular, and cellular mechanisms between tumorigenesis and epileptogenesis represent 'two sides of the same coin'. These include augmented neuronal excitatory ... ...
Abstract | Epilepsy is the most common symptom in patients with brain tumors. The shared genetic, molecular, and cellular mechanisms between tumorigenesis and epileptogenesis represent 'two sides of the same coin'. These include augmented neuronal excitatory transmission, impaired inhibitory transmission, genetic mutations in the BRAF, IDH, and PIK3CA genes, inflammation, hemodynamic impairments, and astrocyte dysfunction, which are still largely unknown. Low-grade developmental brain tumors are those most commonly associated with epilepsy. Given this strict relationship, drugs able to target both seizures and tumors would be of extreme clinical usefulness. In this regard, anti-seizure medications (ASMs) are optimal candidates as they have well-characterized effects and safety profiles, do not increase the risk of developing cancer, and already offer well-defined seizure control. The most important ASMs showing preclinical and clinical efficacy are brivaracetam, lacosamide, perampanel, and especially valproic acid and levetiracetam. However, the data quality is low or limited to preclinical studies, and results are sometimes conflicting. Future trials with a prospective, randomized, and controlled design accounting for different prognostic factors will help clarify the role of these ASMs and the clinical setting in which they might be used. In conclusion, brain tumor-related epilepsies are clear examples of how close, multidisciplinary collaborations among investigators with different expertise are warranted for pursuing scientific knowledge and, more importantly, for the well-being of patients needing targeted and effective therapies. |
---|---|
MeSH term(s) | Humans ; Anticonvulsants/therapeutic use ; Epilepsy/complications ; Levetiracetam/therapeutic use ; Valproic Acid/therapeutic use ; Brain Neoplasms/complications |
Chemical Substances | Anticonvulsants ; Levetiracetam (44YRR34555) ; Valproic Acid (614OI1Z5WI) |
Language | English |
Publishing date | 2023-02-13 |
Publishing country | Netherlands |
Document type | Journal Article ; Review |
ZDB-ID | 80160-4 |
ISSN | 1878-5883 ; 0022-510X ; 0374-8642 |
ISSN (online) | 1878-5883 |
ISSN | 0022-510X ; 0374-8642 |
DOI | 10.1016/j.jns.2023.120584 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 308: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.